Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-14T04:36:10.406Z Has data issue: false hasContentIssue false
  • English
  • Français

Beyond the Bundle: A Survey of Central Line–Associated Bloodstream Infection Prevention Practices Used in US and Canadian Pediatric Hospitals

Part of: BARRY FARR AWARD RECIPIENTS

Published online by Cambridge University Press:  02 January 2015

Sarah B. Klieger ,
Gail Potter-Bynoe ,
Caroline Quach ,
Thomas J. Sandora  and
Susan E. Coffin
Sarah B. Klieger*
Affiliation:
Division of Infectious Diseases and Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Gail Potter-Bynoe
Affiliation:
Infection Prevention and Control, Boston Children's Hospital, Boston, Massachusetts
Caroline Quach
Affiliation:
Division of Infectious Diseases, Montreal Children's Hospital-McGill University Health Centre, Montreal, Quebec, Canada
Thomas J. Sandora
Affiliation:
Division of Infectious Diseases, Boston Children's Hospital, Boston, Massachusetts
Susan E. Coffin
Affiliation:
Division of Infectious Diseases and Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
*
Division of Infectious Diseases and Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, 3535 Market Street, Suite 1519, Philadelphia, PA 19104 (klieger@email.chop.edu)
Get access Rights & Permissions [Opens in a new window]

Abstract

We surveyed US and Canadian pediatric hospitals about their use of central line-associated bloodstream infection (CLABSI) prevention strategies beyond typical insertion and maintenance bundles. We found wide variation in supplemental strategies across hospitals and in their penetration within hospitals. Future studies should assess specific adjunctive prevention strategies and CLABSI rates.

Type
Concise Communication
Information
Infection Control & Hospital Epidemiology , Volume 34 , Issue 11 , November 2013 , pp. 1208 - 1210
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Miller, MR, Niedner, MF, Huskins, WC, et al. Reducing PICU central line-associated bloodstream infections: 3-year results. Pediatrics 2011;128(5):e1077–e1083. http://pediatrics.aappublications.org/content/128/5/el077.full.html. Published October 24, 2011. Accessed February 8, 2013.CrossRefGoogle ScholarPubMed
2.Schulman, J, Stricof, R, Stevens, TP, et al. Statewide NICU central-line-associated bloodstream infection rates decline after bundles and checklists. Pediatrics 2011;127(3):436–444.CrossRefGoogle ScholarPubMed
3.Dudeck, MA, Horan, TC, Peterson, KD, et al. National Healthcare Safety Network (NHSN) report, data summary for 2010, device-associated module. Am J Infect Control 2011;39(10):798–816.CrossRefGoogle ScholarPubMed
4.Hong, H, Morrow, DF, Sandora, TJ, Priebe, GP. Disinfection of needleless connectors with chlorhexidine-alcohol provides long-lasting residual disinfectant activity. Am J Infect Control 2013; 41 (8):e77–e79. http://www.sciencedirect.com/science/article/pii/S0196655312013739. Published February 7,2013. Accessed April 3, 2013.CrossRefGoogle ScholarPubMed
5.Climo, MW, Sepkowitz, KA, Zuccotti, G, et al. The effect of daily bathing with Chlorhexidine on the acquisition of methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and healthcare-associated bloodstream infections: results of a quasi-experimental multicenter trial. Crit Care Med 2009;37(6): 1858–1865.CrossRefGoogle ScholarPubMed
6.Tamma, PD, Aucott, SW, Milstone, AM. Chlorhexidine use in the neonatal intensive care unit: results from a national survey. Infect Control Hosp Epidemiol 2010;31(8):846–849.CrossRefGoogle ScholarPubMed
7.FDA/Center for Drug Evaluation and Research. Drugs@FDA: FDA approved drug products. ChloraPrep: labeling revision, August 16, 2102. Food and Drug Administration website, http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo. Accessed April 7, 2013.Google Scholar